Sharp Therapeutics (TSXV:SHRX) Other Current Assets: C$0.08 Mil (As of Dec. 2025)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

TSXV:SHRX Sharp Therapeutics Corp TSXV:SHRX
14 GF Score
Price C$0.91
View Full Analysis

What is Sharp Therapeutics Other Current Assets?

Sharp Therapeutics TSXV:SHRX 14 Other Current Assets is C$0.08 Mil as of Dec. 2025. GuruFocus rates TSXV:SHRX with a GF Score™ of 14/100.

Sharp Therapeutics's other current assets for the quarter that ended in Dec. 2025 was C$0.08 Mil.

Sharp Therapeutics's quarterly other current assets declined from Jun. 2025 (C$0.12 Mil) to Sep. 2025 (C$0.11 Mil) and declined from Sep. 2025 (C$0.11 Mil) to Dec. 2025 (C$0.08Mil).

Sharp Therapeutics's annual other current assets declined from Dec. 2023 (C$0.07 Mil) to Dec. 2024 (C$0.05 Mil) increased from Dec. 2024 (C$0.05 Mil) to Dec. 2025 (C$0.08 Mil).


Sharp Therapeutics Other Current Assets Related Terms


Sharp Therapeutics Other Current Assets Historical Data

* Premium members only.

The historical data trend for Sharp Therapeutics's Other Current Assets can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Sharp Therapeutics Other Current Assets Chart

Sharp Therapeutics Annual Data
Trend Dec23 Dec24 Dec25
Other Current Assets
0.07 0.05 0.08

Sharp Therapeutics Quarterly Data
Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25
Other Current Assets Get a 7-Day Free Trial Premium Member Only 0.05 0.19 0.12 0.11 0.08
TSXV:SHRX
14GF Score
Sharp Therapeutics Corp TSXV:SHRX
Other Current Assets is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Sharp Therapeutics Other Current Assets Calculation

Technically, the other current assets line may include any asset that will be used up within the next 12 months. However, other current assets never include assets that are listed elsewhere in the current assets section of the balance sheet. For this reason, other current assets are almost never:


Cash
Trade Receivables
Inventory

The assets grouped under other current assets are most commonly:


Prepaid Expenses
Tax Assets
Non-Trade Receivables
Other (too numerous to list)

Some companies can and do choose to report each of these items separately.

Other current assets may be made up largely of Prepaid Expenses - unless these are listed on a separate line of the balance sheet.

Prepaid expenses are exactly what they sound like. If a company pays a $30 million insurance premium on the last day of June that will provide coverage for the entire month of July, the company will record a $30 million prepaid expense to account for the insurance expense it will show in July that it already paid for in June.

Tax assets can be quite complex. It is not common for companies to have both tax assets and tax liabilities. It is important that investors take note of both items when considering future taxes.

Non-Trade receivables are rarely a large item. They include money owed to the company by non-customers. Non-trade receivables can be caused by related party transactions, the sale of a business unit, etc. The notes to the company's financial statements will often provide much more detail on this item if it is truly important.

There are a variety of other current assets like non-trade receivables which are simply too numerous to list. If a company is following correct reporting procedures, it should not lump items that are different from one another and yet individually important to the company together under the line Other Current Assets.

At most companies, other current assets are a small and unimportant part of the total balance sheet.

Frequently Asked Questions Learn more about Other Current Assets →
What does a Other Current Assets of C$0.08 Mil mean?
Sharp Therapeutics (TSXV:SHRX) has a Other Current Assets of C$0.08 Mil as of Dec. 2025. Other current assets as record on a company's balance sheet not categorized as standard assets. View historical data on Sharp Therapeutics.
Is Sharp Therapeutics' Other Current Assets too high?
Sharp Therapeutics' current Other Current Assets is C$0.08 Mil. Overall, Sharp Therapeutics has a GF Score™ of 14/100, reflecting its overall financial health beyond just this single metric.
How does Sharp Therapeutics' Other Current Assets compare to VRTX and REGN?
Sharp Therapeutics' Other Current Assets of C$0.08 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Other Current Assets for a Biotechnology company?
A good Other Current Assets depends on the Biotechnology industry context. However, Other Current Assets should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Other Current Assets mean?
A high Other Current Assets can signal that a stock is expensive relative to its fundamentals. Other current assets as record on a company's balance sheet not categorized as standard assets. View historical data on Sharp Therapeutics. Sharp Therapeutics's current Other Current Assets is C$0.08 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Sharp Therapeutics stock overvalued right now?
Sharp Therapeutics (TSXV:SHRX) has a current Other Current Assets of C$0.08 Mil. The current Other Current Assets is C$0.08 Mil. Sharp Therapeutics' overall GF Score™ is 14/100. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Other Current Assets calculated?
Other Current Assets is calculated from a company's financial statements. For Sharp Therapeutics (TSXV:SHRX), the current Other Current Assets is C$0.08 Mil as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Sharp Therapeutics Business Description

Address 2403 Sidney Street, Suite 264, Pittsburgh, PA, USA, 15203
Sharp Therapeutics Corp is a preclinical-stage drug discovery company developing therapeutics for genetic diseases. It has developed the patent-protected Disco discovery platform consisting of the CoreX biology, AlloChem chemistry, and Mine computational technologies to discover drugs that selectively activate the protein thats been altered by gene mutation. The company has targeted its discovery engine (Disco) to three hereditary disorders with high unmet need, which include Gauchers Disease, Familial Frontotemporal Dementia, and Niemann Pick Type-C. Its drug development pipeline consists of the following candidates: SEL-148, 721, SEL-148, 742, and SEL-145, 793. Geographically, the company's business operations are carried out in the United States of America.
14GF Score

Get the complete analysis for TSXV:SHRX

Other Current Assets is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

C$0.91
Price